Latest News about BIIB
Recent news which mentions BIIB
10 Health Care Stocks Whale Activity In Today's Session
November 28, 2022
From Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
From Benzinga
2 Stocks Near 52-Week Highs That Could Climb Higher
November 28, 2022
From Motley Fool
From Benzinga
CBOE's Weekly Market Recap: Nov.14-18 – Biogen's Alzheimer's Drug Captures Investors' Attention
November 23, 2022
From Benzinga
TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO
November 21, 2022
From InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
November 17, 2022
From Benzinga
3 Stocks to Avoid Right Now
November 17, 2022
From Motley Fool
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
From Benzinga
Why Is Cassava Sciences (SAVA) Stock Up Today?
November 14, 2022
From InvestorPlace
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
November 14, 2022
From MarketWatch
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
From Benzinga
Why Is AST SpaceMobile (ASTS) Moving Today?
November 14, 2022
From InvestorPlace
Why Is Biogen (BIIB) Stock Up Today?
November 14, 2022
From InvestorPlace
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
November 14, 2022
From Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
From Benzinga
Why Are Healthcare Stocks Down Today?
November 11, 2022
From InvestorPlace
The Power of McKinsey
November 09, 2022
From Motley Fool
From Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
October 29, 2022
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 28, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
October 26, 2022
From Benzinga
Is Biogen a Buy After It Boosted Guidance?
October 26, 2022
From Motley Fool
From MarketWatch
Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition
October 25, 2022
Tickers
BIIB
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.